ETD002 + salbutamol

ETD002 + salbutamol is a combination drug intended for respiratory indications. **ETD002** is an investigational small molecule activator of TMEM16A (anoctamin-1), a calcium-activated chloride channel, being developed for cystic fibrosis and potentially other chronic obstructive pulmonary diseases[6]. It enhances chloride transport independently of CFTR, promoting airway hydration and improved mucociliary clearance. **Salbutamol** is a well-established short-acting beta-2 adrenergic receptor agonist (bronchodilator) approved for asthma and COPD. It relaxes bronchial smooth muscle by stimulating the beta-2 adrenoceptor, increasing intracellular cAMP and inhibiting myosin phosphorylation, resulting in airway dilation and improved breathing[1][5]. The rationale for combining ETD002 and salbutamol would be to provide synergistic effects on airway hydration, bronchodilation, and overall respiratory function for diseases like cystic fibrosis, asthma, or COPD[6].